Darius Beh

ID & IPC physician 🇸🇬 | Spin enthusiast | 🍝🍜 maker | new 🐯dad | thoughts shared are my own

[Infection Control Today @ICT_magazine]

Recognition matters in infection prevention.

Nominate the educator or mentor raising the bar in your network for ICT's 2026 Educator of the Year and Rising Educator Award.

🔗 Submit your nomination: https://t.co/820Rg70Xap

#InfectionControlToday #InfectionPrevention

[Darius Beh @docdarius]

… there’s no consensus on judging the possible danger of a virus made by an A.I. model. “What is the risk of what I’ve never seen before?”…

**The risk is that the human immune system has no defense against such a pathogen**

[Raina MacIntyre @Globalbiosec]

AI just created a virus not found in nature. gift article . https://t.co/tNLouH5Knu

[Tedros Adhanom Ghebreyesus @DrTedros]

Every breakthrough begins with hope. EBO-PEP—the first clinical trial evaluating post-exposure prophylaxis (PEP) with obeldesivir for #Ebola disease to Bundibugyo virus is launched. If effective among high-risk contacts after exposure, this could mark a major step forward in Ebola BVD prevention.

We thank @inrb_kinshasa, @agenceANRS and ALIMA for their leadership and partnership on this important trial. @WHO will continue to support.

https://t.co/ByowHhXNaY

[World Health Organization (WHO) @WHO]

#Cancer is not just a disease.

It is a family story, a caregiving story, a community story.
Many of us may navigate it - after receiving the diagnosis or as a friend or family member providing care and support.

It can be tough. But there is hope.

Stronger prevention, better earlier detection, quality treatment and palliative care, when available to everyone — can change the outcome of your cancer journey https://t.co/W9hhPYJsGI

[Jason Gale @jwgale]

1/6
The @WHO-sponsored PARTNERS trial has begun testing experimental therapies — MBP134 (2 monoclonal Abs), remdesivir (antiviral), and a combination of both against supportive care — for Bundibugyo Ebola virus disease in DRC.

https://t.co/fMogq2xAlM

[Helen Branswell 🇨🇦 @HelenBranswell]

#Ebola update: As if 7/2, DRC has confirmed 1502 Ebola cases; 473 of those people have died. That's 42 additional cases. 11,360 case contacts have been identified; 82% of them are being followed. https://t.co/2CJdzmQBu9

[World Health Organization (WHO) @WHO]

"Earlier today, the clinical trial of two therapeutics began, with the enrolment of the first patient.

The PARTNERS trial will evaluate the monoclonal antibody MBP134 and the antiviral drug remdesivir, alone and in combination.

The study is being coordinated by the #DRC’s National Institute for Biomedical Research, supported by a coalition of partners including WHO, and conducted in close cooperation with the affected communities.

Patients who enroll in the trial will receive comprehensive supportive care and close follow-up.

We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial"-@DrTedros #Ebola

https://t.co/MvPDi8wJol

[Darius Beh @docdarius]

@Globalbiosec Though it does not prevent exposure, we also need to fit pre-exposure vaccination and PEP nicely somewhere in this pyramid so that institutions focus on this for healthcare workers.

[Dr. Ali Khan @DrAliSKhan]

Update on Ebola. Still spreading with 808 cases, including 192 death since the outbreak was declared in DRC on May 15, 2026. Continued community deaths and only 50% of reported contacts are being followed. Expect continued expansion. No cases for 11 days in Uganda. None in Rwanda.
https://t.co/JG8sqeQZN2

[Darius Beh @docdarius]

How Ebola Spreads Through Gold Mining https://t.co/aOo6WQ7whi via @NYTimes

The possible association of mining, exposure to fruit bats and Ebola.

[Anatoli Kopadze @AnatoliKopadze]

https://t.co/AAWIZD1pNL

[The National Special Pathogen System (NSPS) @The_NSPS]

Join NETEC on May 19 for a Hantavirus Town Hall focused on:
▪️ PPE practices
▪️ Laboratory considerations
▪️ Waste management
▪️ Frontline preparedness

📅 May 19
🕑 2 PM ET

Featuring experts from @EmoryUniversity, @BellevueHosp & @NebraskaMed.

Register: https://t.co/chQhGfNMK3

[Darius Beh @docdarius]

My first impression when hearing about this was that it was unusually large at the outset, implying that this outbreak was detected late and that it has been spreading for a while.

[Craig Spencer MD MPH @Craig_A_Spencer]

There's a new Ebola outbreak in the DR Congo.

I'm already getting lots of questions, so let me tell you what you should know:

* This one is already big — "over 246 suspected cases and 65 deaths have been reported". This means we're just learning about this outbreak long after its already been spreading. This makes it harder to find contacts and all the cases. Most outbreaks don't get this big by the time they're over, let alone this big by the time we even recognize them.

* This one is in a really tough place — the outbreak is centered around the east of DR Congo, in a place with a lot of conflict, cross-border traffic, and instability. There may also be cases in the big city here, meaning worry for more/faster spread in an urban environment. I've worked up here, it's a tough spot to get to and work in, due to transport and conflict. There was an Ebola outbreak here in 2018-2019 that grew to over 3,000 cases.

* This is on a few borders — this outbreak is close to the Uganda and South Sudan borders. Uganda has a lot of experience with Ebola outbreaks, South Sudan less. Very possible there's already been cross-border cases, given size of the outbreak already. WHO and countries will be stepping up surveillance, but again, this is a place with a lot of conflict and instability.

* This is not your normal Ebola — most outbreaks have been of the Zaire strain of Ebola. That's the one we have vaccines and treatments for. But this outbreak appears to be due to the Bundyibugyo strain. This has caused a few outbreaks in DR Congo in the past, as well as over the border in Uganda. BUT there is no vaccine, and no treatment for this strain.

My initial reaction here is that this isn't good, at all. I'm glad Africa CDC is on it, as is WHO. But delayed recognition means this has already gotten big, at a confluence of borders with a lot of instability, and for a strain that we don't have any vaccines or treatments for.

I'll share updates as I hear them

[ESCMID @ESCMID]

☀️Registration for ESCMID's 24th Summer School is open, so book your spot today! https://t.co/I6qnLzCnnO

This exciting one week offers a chance to connect with professionals from around the world & build on relevant skills for one's career development. 📚

Register by 05 June!

[nature @Nature]

Brazil’s federal police arrested a researcher late last month for allegedly taking samples of viruses from a high-security biosafety laboratory at a leading Brazilian university.

https://t.co/6Ga5XjtZJE

[The National Special Pathogen System (NSPS) @The_NSPS]

🚨 SitRep Alert | Lassa Fever in Nigeria 🚨

Cases are rising, with higher fatality rates and growing impact on healthcare workers.

🎥 Dr. Gavin Harris (@emoryuniversity) shares what clinicians + public health teams need to know.

➡️ Resources: https://t.co/sKh0RjQwmO

#SitRep

[Doctors Without Borders (MSF) in Asia Pacific @MSF_APAC]

Sleeping sickness is almost always fatal w/o treatment. For years, doctors had only arsenic-derived drugs that were toxic. Today, hope is emerging: Our partner organisation, DNDi, has recently had approval for a ground-breaking new drug, acoziborole, which can cure it w/ 1 dose.

[Eric Topol @EricTopol]

A single dose of antibiotics can have lasting effects on your gut microbiome, with changes that last well beyond 4 years. Three types of antibiotics stood out for their long term disruptive impact (3 at left, Figure)
@NatureMedicine
https://t.co/ObWU56P9Bd

[Tedros Adhanom Ghebreyesus @DrTedros]

Congratulations to #Singapore – the first country in the @WHOWPRO Region to achieve the highest maturity level (ML4) in WHO's classification of regulatory authorities for medical devices. This milestone reflects Singapore’s commitment to ensuring access to quality medical products and protecting patients from substandard and falsified products.

@WHO stands ready to support Member States strengthen their national regulatory authorities.

[Darius Beh @docdarius]

Increase in Lassa cases in Nigeria with a higher CFR… Something to watch.

[Emory University SCDP @EmoryScdp]

On February 26, 2026 Region IV Special Pathogens of Concern Situation Report, Gavin Harris, MD, covers current special pathogens of concern. Click the link below to access the situation report. https://t.co/kqCpf01dyZ